<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114404">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02033967</url>
  </required_header>
  <id_info>
    <org_study_id>MLN_SVV_CVP</org_study_id>
    <nct_id>NCT02033967</nct_id>
  </id_info>
  <brief_title>Vasodilator-induced Hypovolemia in Living Liver Donors</brief_title>
  <official_title>Vasodilator-induced Hypovolemia in Living Liver Donors: Central Venous Pressure-guided vs Stroke Volume Variation-guided Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induced hypovolemia is known to improve surgical field during living donor hepatectomy. This
      procedure is conventionally guided by monitoring the central venous pressure (CVP). Stroke
      volume variation (SVV) is a novel method to substitute with CVP to monitor cardiac preload.
      The investigators try to evaluate the relationship between CVP and SVV during CVP-guided
      vasodilator induced hypovolemia (validation study). Then, feasibility of vasodilator induced
      hypovolemia using the SVV calculated from the validation study will be tested (feasibility
      study).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-phases study.

      first phase validation study : Evaluation of the relationship between CVP and SVV during
      CVP-guided vasodilator induced hypovolemia

      second phase feasibility study

      : Comparison of the surgical field grade between validation study group(CVP guided group)
      and feasibility study group(SVV guided group)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>target value of SVV</measure>
    <time_frame>during living donor hepatectomy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Target value of SVV is calculated from the linear regression equation that was calculated from scatter plot made with CVP and SVV values during CVP-guided vasodilator induced hypovolemia (validation study).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>surgical field</measure>
    <time_frame>during living donor hepatectomy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>&lt;4 point scale&gt; Grade l: Very lax IVC and hepatic veins, minimal bleeding at resection plane, very easy to operate Grade ll: Lax IVC and hepatic veins, a little bleeding at resection plane, easy to operate Grade lll: Tense IVC and hepatic veins, appreciable bleeding at resection plane, somewhat difficult to operate Grade lV: Very tense IVC and hepatic veins, profuse bleeding at resection plane, very difficult to operate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>use of inotropics</measure>
    <time_frame>during living donor hepatectomy</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated blood loss</measure>
    <time_frame>during living donor hepatectomy</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>CVP and SVV During Living Donor Hepatectomy</condition>
  <condition>Surgical Field Grade (Condition of Surgical Field; Bleeding, Tension of the IVC)</condition>
  <arm_group>
    <arm_group_label>CVP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CVP-guided vasodilator-induced hypovolemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SVV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SVV-guided vasodilator-induced hypovolemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vasodilator induced hypovolemia</intervention_name>
    <arm_group_label>CVP</arm_group_label>
    <arm_group_label>SVV</arm_group_label>
    <other_name>Milrinone induced hypovolemia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult (20-60 yr)

          -  elective living liver donors

        Exclusion Criteria:

          -  not obtained informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chul-Woo Jung, MD</last_name>
    <email>spss@dreamwiz.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul national University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeonghee Cha</last_name>
      <email>Jeonghee.cha@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Chul-Woo Jung</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>liver donor</keyword>
  <keyword>hepatectomy</keyword>
  <keyword>vasodilator</keyword>
  <keyword>central venous pressure</keyword>
  <keyword>stroke volume variation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vasodilator Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
